LBA2Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC). (25th November 2018) - Zhou, C; Lu, Y; Kim, S-W; Reungwetwattana, T; Zhou, J; Zhang, Y; He, J; Yang, J-J; Cheng, Y; Lee, S H; Bu, L; Xu, T; et al.